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The addition of short-term androgen deprivation therapy
(ADT) to salvage radiotherapy post radical prostatectomy
was recently reported in a multi-centre, phase 3, randomised
controlled trial (RCT) by Carrie et al. (2016) to improve
biochemical and clinical progression free survival at 5 years.
The cohort consisted of men with a PSA level of <0.1 for
at least 6 months after radical prostatectomy, with salvage
radiotherapy commenced at PSA levels between 0.2 μg/L
and 2.0 μg/L (1). The primary endpoint was progression-free
survival deﬁned as time from randomisation to documented
“biological” progression (including a rising PSA),
clinical progression or death from any cause. The 5-year
progression-free survival was 62% in the external beam
radiotherapy (EBRT) alone group and 80% in those who
received radiotherapy plus goserelin (P<0.0001). With
a halving of the rate of progression (hazard ratio 0.50,
P<0.0001), the median duration between randomisation
and relapse was increased by 10 months with the addition
of ADT to EBRT (P=0.0001). No systematic tests were
done to assess testosterone recovery after ADT: the delay
in progression was remarkably similar to the expected
total duration of castration (therapy plus recovery time)
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associated with 6 months of goserelin therapy (2). Whether
this result is a simple delay of recurrence or secondary to
higher rates of cure is unable to be determined at this time
point. There has however been no impact on overall survival
as yet, with median overall survivals being 56 months for
the EBRT alone group versus 58 months for the combined
treatment group.
While 589 (80%) of men had a PSA titre of <0.5 μg/L
at randomisation (305 and 284 in the EBRT and combined
groups respectively), other known risk factors for
radiotherapy failure classified 70% of the cohort as high
risk meaning that there was a significant risk of extra-pelvic
disease in the cohort a priori. Subgroup analyses showed
no significant restriction of therapeutic benefits to any
particular subgroup.
Although the authors suggest these data may be
considered evidence of castration working in synergy to
radiosensitise EBRT, it must be kept in mind that the
ADT in the study was goserelin monotherapy (i.e., no
antiandrogen was used) administered on day 1 of EBRT.
As this drug will cause an initial “flare” in testosterone,
followed by a slow fall over a couple of weeks, it is unlikely
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that a period of castration was present during the initial
delivery of EBRT to interact with the local therapy.
As expected, systemic adverse effects with ADT were
troublesome having been registered as acute adverse events
for 30 (8%) of 366 at grade 2 or worse. The addition of
ADT does not appear to have contributed to the toxicity
of EBRT, with no differences in rates of genitourinary
(GU) or gastrointestinal (GI) toxicity at any level. Overall,
grade 2 or more toxicity levels were commensurate with
the technology used to deliver the EBRT at approximately
12% and 13% for GU and GI acutely. Severe (Grade 3
or worse) late toxicity was not different between groups
at approximately 8% and 2% for GU and GI toxicity,
respectively. Unfortunately, only 55% of men returned
the 1 year follow up health related quality of life (QoL)
surveys (QLQ-C30) and only 22% for the 5 year follow up
survey. Of those returning QoL questionnaires, a higher
proportion of men had global QoL deteriorations in the
combined therapy arm (35%) than in the radiation only
arm (26%) at 1 year compared with baseline. No differences
were apparent at 5 years however, with approximately 50%
and 30% having registered stable or worsened global QoL
levels, respectively, in each arm. No differences were seen
between arms in terms of sexual function, which reduced
from a median QLQ-PR25 score of 50 at baseline to 42 at
1 year and 33 at 5 years.
Completing an RCT such as this in 43 French study
centres is an outstanding achievement and the authors are
to be congratulated. However there are notable deficiencies,
many of which are acknowledged in the manuscript.
There was no central review of pathology specimens or of
progression, which is important given the stated primary
outcome of the trial. Metastatic progression data were
not available as this was only recorded if it occurred as
part of ﬁrst progression. Early QoL data were collected at
12 months post-randomisation when most acute EBRT and
ADT toxicity would be expected to have mostly settled, and
thus limits interpretation. Compliance for QoL surveys was
also poor as previously stated.
Will these data impact contemporary practice?
Considerable progress has been seen with cancer imaging
recently, particularly with magnetic resonance imaging
(MRI) and positron emission tomography (PET) in relation
to prostate cancer. In health care systems that have seen a
rapid uptake of small-ligand prostate specific membrane
antigen (PSMA) PET or choline PET, a significant
proportion of patients eligible for this study would now
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have metastases identified outside the salvage radiotherapy
field by these scans (3). In these cases, men avoid salvage
radiotherapy that would not positively impact on their
progression or survival.
Five years is a short time for determining the primary
endpoint of this trial viz. progression-free survival, so
further reports are to be expected. Nevertheless, these
results in a patient cohort with a high risk of progression
after post-operative salvage radiotherapy, show use of ADT
in an adjuvant manner is beneficial in delaying short term
progression and is generally supportive of the findings of
previous retrospective studies (4) and that of the RTOG
9601 study (5). However, because of the issues raised above,
the veracity of the findings and the subsequent ability to
justify this approach as standard therapy may need to be
re-evaluated in the era of improving radiological staging
techniques.
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